AU2023243776A1 - Nitrogen-containing heterocyclic compound, preparation method therefor, and pharmaceutical application thereof - Google Patents

Nitrogen-containing heterocyclic compound, preparation method therefor, and pharmaceutical application thereof Download PDF

Info

Publication number
AU2023243776A1
AU2023243776A1 AU2023243776A AU2023243776A AU2023243776A1 AU 2023243776 A1 AU2023243776 A1 AU 2023243776A1 AU 2023243776 A AU2023243776 A AU 2023243776A AU 2023243776 A AU2023243776 A AU 2023243776A AU 2023243776 A1 AU2023243776 A1 AU 2023243776A1
Authority
AU
Australia
Prior art keywords
heterocyclyl
alkyl
group
cycloalkyl
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023243776A
Other languages
English (en)
Inventor
Huaide DONG
Feng He
Xin Li
Weikang Tao
Bin Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Hengrui Pharmaceutical Co Ltd
Jiangsu Hengrui Pharmaceutical Co Ltd
Original Assignee
Shanghai Hengrui Pharmaceutical Co Ltd
Jiangsu Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Hengrui Pharmaceutical Co Ltd, Jiangsu Hengrui Pharmaceutical Co Ltd filed Critical Shanghai Hengrui Pharmaceutical Co Ltd
Publication of AU2023243776A1 publication Critical patent/AU2023243776A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2023243776A 2022-03-28 2023-03-28 Nitrogen-containing heterocyclic compound, preparation method therefor, and pharmaceutical application thereof Pending AU2023243776A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN202210330007 2022-03-28
CN202210330007.4 2022-03-28
CN202210944231 2022-08-05
CN202210944231.2 2022-08-05
CN202211255163.5 2022-10-13
CN202211255163 2022-10-13
PCT/CN2023/084265 WO2023185793A1 (zh) 2022-03-28 2023-03-28 含氮杂环类化合物、其制备方法及其在医药上的应用

Publications (1)

Publication Number Publication Date
AU2023243776A1 true AU2023243776A1 (en) 2024-09-12

Family

ID=88199144

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023243776A Pending AU2023243776A1 (en) 2022-03-28 2023-03-28 Nitrogen-containing heterocyclic compound, preparation method therefor, and pharmaceutical application thereof

Country Status (10)

Country Link
US (1) US20250206760A1 (https=)
EP (1) EP4501925A4 (https=)
JP (1) JP2025509995A (https=)
KR (1) KR20240167844A (https=)
CN (1) CN118715216A (https=)
AU (1) AU2023243776A1 (https=)
CA (1) CA3253847A1 (https=)
MX (1) MX2024011705A (https=)
TW (1) TW202345816A (https=)
WO (1) WO2023185793A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
CN121969632A (zh) * 2023-09-27 2026-05-01 江苏恒瑞医药股份有限公司 一种喹唑啉衍生物的可药用盐、其结晶形式及用途
CN121969633A (zh) * 2023-09-27 2026-05-01 江苏恒瑞医药股份有限公司 一种喹唑啉衍生物的结晶形式及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1292591B1 (en) * 2000-06-22 2005-02-02 Pfizer Products Inc. Substituted bicyclic derivatives for the treatment of abnormal cell growth
DK1660090T3 (da) * 2003-08-14 2012-12-17 Array Biopharma Inc Quinazolin-analoger som receptor-tyrosinkinase-inhibitorer
ATE446294T1 (de) * 2005-11-15 2009-11-15 Array Biopharma Inc N4-phenyl-chinazolin-4-aminderivate und verwandte verbindungen als inhibitoren der erbb-typ-i- rezeptortyrosinkinase zur behandlung hyperproliferativer krankheiten
AR092289A1 (es) * 2011-11-14 2015-04-15 Sunshine Lake Pharma Co Ltd Derivados de aminoquinazolina y sus sales y metodos de uso
CN104744446B (zh) * 2013-12-30 2019-06-25 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
WO2017148391A1 (zh) 2016-03-01 2017-09-08 上海医药集团股份有限公司 一种含氮杂环化合物、制备方法、中间体、组合物和应用
TWI858848B (zh) * 2018-05-08 2024-10-11 大陸商迪哲（江蘇）醫藥股份有限公司 ＥｒｂＢ受體抑制劑
EP4523755A3 (en) * 2018-09-18 2025-06-11 F. Hoffmann-La Roche AG Quinazoline derivatives as antitumor agents
EP4100409B1 (en) 2020-02-03 2024-08-28 Boehringer Ingelheim International GmbH [1,3]diazino[5,4-d]pyrimidines as her2 inhibitors
JP7626774B2 (ja) 2020-02-03 2025-02-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ＨＥＲ２阻害薬としての［１，３］ジアジノ［５，４－ｄ］ピリミジン
WO2021179274A1 (en) * 2020-03-13 2021-09-16 Suzhou Zanrong Pharma Ltd. ErbB RECEPTOR INHIBITORS AS ANTI-TUMOR AGENTS
US11608343B2 (en) 2020-04-24 2023-03-21 Boehringer Ingelheim International Gmbh Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors
WO2021231400A1 (en) 2020-05-12 2021-11-18 Accutar Biotechnology, Inc. Bis-aryl ethers containing n-acyl azetidine as egfr/her2 inhibitors
TW202214654A (zh) 2020-06-10 2022-04-16 大陸商江蘇恆瑞醫藥股份有限公司 稠合喹唑啉類衍生物、其製備方法及其在醫藥上的應用
TW202214641A (zh) 2020-06-30 2022-04-16 美商艾瑞生藥股份有限公司 Ｈｅｒ２突變抑制劑
US20240398805A1 (en) * 2021-02-05 2024-12-05 Accutar Biotechnology Inc. Quinazoline derived compounds as egfr inhibitors and their uses thereof
WO2023154124A1 (en) * 2022-02-09 2023-08-17 Enliven Therapeutics, Inc. Acylated heterocyclic quinazoline derivatives as inhibitors of erbb2

Also Published As

Publication number Publication date
US20250206760A1 (en) 2025-06-26
JP2025509995A (ja) 2025-04-11
CN118715216A (zh) 2024-09-27
EP4501925A4 (en) 2025-08-27
KR20240167844A (ko) 2024-11-28
CA3253847A1 (en) 2025-07-04
EP4501925A1 (en) 2025-02-05
MX2024011705A (es) 2024-11-08
WO2023185793A1 (zh) 2023-10-05
TW202345816A (zh) 2023-12-01

Similar Documents

Publication Publication Date Title
TWI741423B (zh) 雜芳類衍生物調節劑、其製備方法和應用
AU2023243776A1 (en) Nitrogen-containing heterocyclic compound, preparation method therefor, and pharmaceutical application thereof
AU2019216728B2 (en) Heteroaryl pyridone and aza-pyridone compounds as inhibitors of Btk activity
AU2019231551B2 (en) Substituted 1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-ones
CA2710046C (en) N3-heteroaryl substituted triazoles and n5-heteroaryl substituted triazoles useful as axl inhibitors
AU2007341937B2 (en) Polycyclic heteroaryl substituted triazoles useful as Axl inhibitors
JP6204568B2 (ja) タンパク質キナーゼ阻害剤としての縮合複素環化合物
EP2143724B1 (en) Nitrogenated fused ring derivative, pharmaceutical composition comprising the same, and use of the same for medical purposes
IL282622A (en) Substituted tricyclic compounds as fgfr inhibitors
KR20150108389A (ko) 치환된 피롤로피리미딘 화합물, 이의 조성물 및 이에 의한 치료 방법
CN102762565A (zh) 吡啶并[3,2-d]嘧啶PI3δ抑制剂化合物及使用方法
CA2838784A1 (en) Pyrazolo[3,4-c]pyridine compounds and methods of use
CA2710043A1 (en) Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as axl inhibitors
AU2022280845A1 (en) Nitrogen-containing heterocyclic compound, preparation method therefor, and application thereof in medicines
AU2020386587A1 (en) Pyrazolo-heteroaryl derivative, preparation method therefor, and medical use thereof
AU2021385752A1 (en) Fused tricyclic compound, preparation method therefor and application thereof in medicine
AU2019344878B2 (en) Aromatic heterocyclic compound with kinase inhibitory activity
AU2021238799A1 (en) Fused bicyclic derivative, preparation method therefor, and pharmaceutical use thereof
CN119855817A (zh) 杂环炔基取代的酰胺衍生物、其制备方法及其应用
CN117903172A (zh) 取代的含氮杂芳基类化合物、其制备方法及其在医药上的应用
EA052991B1 (ru) Азотсодержащее гетероциклическое соединение, способ его получения и его фармацевтическое применение
EP4310081A1 (en) Ctla-4 small molecule degradation agent and application thereof
AU2014200824B2 (en) Substituted triazoles useful as Axl inhibitors
CN120574235A (zh) 多环类化合物、其制备方法及其在医药上的应用
AU2016259396A1 (en) Substituted triazoles useful as Axl inhibitors